TP53 and neoplasm: Mechanistically, HF administration upregulated phosphorylated p53 (Ser15) and p21 within tumor tissues, while downregulating key cell cycle regulators such as cyclin D1, CDK4, and CDK6, providing in vivo evidence for activation of the p53/p21 axis and G0/G1 phase arrest.